- GMP
- Reviews
- Subscription
- Allotment
Valiant Laboratories IPO GMP, Guidance, Subscription & listing @ Chanakyanipothi.com, India`s Oldest Investment & IPO website.
A legacy of 31 Years.
Most Trusted by Investors across India.
Valiant Laboratories IPO Listing Review:
The scrip issued at Rs. 160 is listed at Rs. 162.15, marginal premium of Rs 2.15 over its issue price.
Why should you apply Valiant Laboratories IPO? Review:
The company is an Active Pharmaceutical Ingredient (“API”) / Bulk Drug manufacturing company, with steady and good profitability track-record. The offer price is quite reasonable. The IPO size is also very small in mainboard category. Huge oversubscription expected, in spite of large number of IPOs. Apply
Valiant Laboratories IPO Grey Market Premium
Premium: Rs.20
Kostak Rs. –
BHni/SHni Subject to price Rs. 20500
Subscription Status of Valiant Laboratories IPO
On 3 October 2023 @ 5.00 (Day 4) Closed
Review: Trend improved on Day 4
QIB: 2178030 Shares 20.83 T
NII(10L+): 1088999 Shares 63.62 T
NII (<10L) 544501 Shares 78.64 T
NII (Total) 1633500 Shares 73.63 T
RII: 3811500 Shares 16.04 T
Total: 7623030 Shares 29.75 T
Who is the promoter of Valiant Laboratories IPO?
SHANTILAL SHIVJI VORA AND DHANVALLABH VENTURES LLP
What is the business of Valiant Laboratories?
Valiant Laboratories is an Active Pharmaceutical Ingredient (“API”) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol , is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. We manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers. Paracetamol was initially approved by the U.S. Food and Drug Administration (“US FDA”) in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (“OTC”) allergy medications, cold medications, sleep medications, pain relievers, and other products.
Its manufacturing facility is located at Plot nos. L-13 and L-30, Tarapur Industrial Area, Boisar, Palghar
– 401506, in the state of Maharashtra, India which is spread over an aggregate parcel of land admeasuring about 2,000 sq. mts. with an aggregate annual total installed capacity of 9,000 MT per annum. The Manufacturing Facility employs modern machinery and equipment to ensure smooth flow of operations. It is holding certificate of good manufacturing practices (GMP) for manufacture and sale of bulk drugs / API and ISO 9001:2015 certification.
Its quality control team monitors the manufacturing process at all stages from initial testing stage for incoming raw material to the final product prior to packing. Within its Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra it aso has an in-house R&D infrastructure.
The Company is promoted by Shantilal Shivji Vora, Director and Dhanvallabh Ventures LLP.
Shantilal Shivji Vora has over 45 years of experience in chemical and pharmaceutical industry
The company, through its wholly owned subsidiary, Valiant Advanced Sciences Private Limited intend to establish a greenfield project at Saykha Industrial Area, Bharuch, Gujarat, which shall be spread over an aggregate parcel of land admeasuring about 57,766 sq. mtrs. (“Proposed Facility”) which shall venture into manufacture of speciality chemicals such as ketene and diketene derivative products. One of these products namely, acetic anhydride is used as a raw material in the process of manufacture of paracetamol.
To get more information about the company, click www.valiantlabs.in
What is the object of Valiant Laboratories IPO?
The Company proposes to utilise the Net Proceeds towards funding the following objects:
1. Investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited
for part-financing its capital expenditure requirements in relation to the setting up of a
manufacturing facility for speciality chemicals at Saykha Industrial Area, Bharuch, Bharuch,
Gujarat (“Proposed Facility”);
2. Investment in VASPL for funding its working capital requirements; and
3. General corporate purposes
Valiant Laboratories IPO GMP, details & review
Valiant Laboratories IPO Details | |
IPO opens on | 27 September ,2023 |
IPO closes on | 3 October ,2023 |
Issue Type | Book Built Issue IPO |
Issue Size | 10890000 Sh /Rs 152.46 Cr |
* Fresh Issue | 10890000 Sh /Rs 152.46 Cr |
* Offer for Sale | – |
Face Value per share: | Rs. 10 |
Price Band | Rs. 133-140 |
Retail Discount | Rs 0 per share |
Employee discount | Rs. 0 per share |
Retail Lot Size | 105 Shares |
Listing will at | BSE, NSE |
Shares offered to | Shares | Rs. in Cr |
QIB (50 %) | 5445000 | 76.23 |
NII (15 %) | 1633500 | 22.87 |
RII (35 %) | 3811500 | 53.36 |
Employees | X | – |
Total Shares | 10890000 | 152.46 |
Retail portion will be oversubscribed by | X Forms. | |
How to apply in Valiant Laboratories IPO? | Rs. | |
Min Retail Application | 105 Sh | 14,700 |
Max Retail Application | 1365 Sh | 191,100 |
Small HNI (Min) application | 1470 Sh | 205,800 |
Small HNI (Max) application | 7140 Sh | 999,600 |
Big HNI Application | 7245 Sh | 1014,300 |
Timetable of Valiant Laboratories IPO | |
IPO opens on | 27 September 2023 |
IPO Closes on | 3 October 2023 |
IPO Allotment on | 5 October 2023 |
Unblocking of ASBA | 6 October 2023 |
Credit of Shares | 6 October 2023 |
Listing on | 6 October 2023 |
Registered Office of Valiant Laboratories | |
104, Udyog Kshetra, Mulund Goregaon Link Road, Mulund West, Mumbai- 400080, Maharashtra | |
Lead Managers of Valiant Laboratories IPO Unistone Capital Pvt ltd |
|
Registrar to IPO | |
Link Intime India Private Limited |
Valiant Laboratories IPO Financial & Analytical Ratios | ||||
Year | Total Income | Net Profit | EPS | RoNW |
Rs. in Cr | Rs.in Cr | Rs. | % | |
2020-21 | 183.78 | 30.59 | 10.8 | 34.54 |
2021-22 | 293.47 | 27.49 | 9.52 | 38.48 |
2022-23 | 338.77 | 29.00 | 8.91 | 28.86 |
Book Value of the Share on 31.03.2023 | Rs. | 30.86 | ||
BV of the Share after the IPO | Rs. | 0 | ||
Offer Price at Cap | Rs. | 140 |
Ratio Analysis | |
Upper Price /last EPS | 15.71 |
Price/Book Value Ratio | 4.54 |
Price/BV after IPO | ? |
Valiant Laboratories IPO GMP, details & Guidance
Which are the companies which can be compared with Tata Technologies? Study Peer Comparison.
As on date of RHP | Total Income Rs. | Face | PE |
Income | Value | Ratio of | |
Rs. In Cr | Rs | ||
The IPO Company | 334 | 10 | 15.71 |
Granules India | 4512 | 1 | 83.10 |
Jagsonpal Pharma | 236.71 | 1 | 40.92 |
– | – | ||
X | – | – | – |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
>>Go to Mainboard IPOs Section: Click
>>Go to SME IPOs Section: Click
>>Get Good Staff or Job, Click: Staffavailable.com
>>Interested in Used Automobiles or vintage cars? Click: BigGaddi.com
>>Get solid Guidance on Mutual fund Investments, Click: ChanakyaMFGuidance.com
>>Study Stock Research Reports, Click: AnalysisLibrary.com
>>Interested in Crossword Puzzles? Click: Magajmari.com
Linkin Time has completed allotment of shares and unblocking within 36 hours of closing of IPO.
Nice work.